Genetic aberrations affecting Wnt signaling have been directly implicated in human cancer. Recent studies have identified frizzled (fz) proteins as Wnt receptors, but the complexity of ligand receptor interactions elucidated to date suggests that other components remain to be defined. Identification of the critical effectors of Wnt transforming action, as well as the specific consequences of Wnt activation will require further investigation.
Aims of this grant include exploration of novel functions (uncovered by the applicant and his colleagues) of a prototype Wnt receptor, Hfz1, structure/function analysis of this and other fzs, and immunoaffinity purification and identification of proteins in the receptor complex. The applicant would then use this knowledge to investigate novel mechanisms of Wnt activation in tumor cells. A second major aim would be to elucidate mechanisms of transformation by Wnt and/or increased beta-catenin levels through investigation of alterations induced in normal cells. The role and contribution of Wnt target gene activation in the transformed phenotype in vitro and in vivo will be explored, and the applicant will also search for novel effectors by application of expression array analysis.
The final aim will be to characterize new mechanisms of Wnt signaling activation in breast and other human tumor cells.
This aim i s supported by the applicant's identification of human tumor cell lines with elevated uncomplexed beta-catenin levels in the absence of genetic lesions affecting APC or beta-catenin. Wnt inhibitors, also characterized by the applicant, will be used to establish evidence of autocrine transforming or other novel mechanisms of Wnt activation. Finally, the effects of downregulation of Wnt signaling in human tumor cells could provide insights into the molecular basis for activation of the Wnt pathway in tumor evolution as well as the potential for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA071672-04
Application #
6200607
Study Section
Pathology B Study Section (PTHB)
Program Officer
Woodhouse, Elizabeth
Project Start
1997-07-01
Project End
2005-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
4
Fiscal Year
2000
Total Cost
$381,375
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
114400633
City
New York
State
NY
Country
United States
Zip Code
10029
Grumolato, Luca; Liu, Guizhong; Haremaki, Tomomi et al. (2013) ?-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factors. PLoS Genet 9:e1003603
Shapiro, Mark; Akiri, Gal; Chin, Cynthia et al. (2013) Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. Ann Surg 257:548-54
Vijayakumar, Sapna; Liu, Guizhong; Rus, Ioana A et al. (2011) High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/?-catenin target gene, CDC25A. Cancer Cell 19:601-12
Asciutti, S; Akiri, G; Grumolato, L et al. (2011) Diverse mechanisms of Wnt activation and effects of pathway inhibition on proliferation of human gastric carcinoma cells. Oncogene 30:956-66
Hall, Christopher L; Zhang, Honglai; Baile, Shobun et al. (2010) p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1. Cancer Res 70:9916-26
Grumolato, Luca; Liu, Guizhong; Mong, Phyllus et al. (2010) Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors. Genes Dev 24:2517-30
Akiri, G; Cherian, M M; Vijayakumar, S et al. (2009) Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene 28:2163-72
Liu, Guizhong; Vijayakumar, Sapna; Grumolato, Luca et al. (2009) Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells. J Cell Biol 185:67-75
Hall, Christopher L; Dubyk, Cara W; Riesenberger, Tracy A et al. (2008) Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 10:797-803
Hall, Christopher L; Daignault, Stephanie D; Shah, Rajal B et al. (2008) Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate 68:1396-404

Showing the most recent 10 out of 25 publications